Effective tumor immunity to melanoma mediated by B16F10 cancer stem cell vaccine

Zhao, Fengshu; Zhang, Rong; Wang, Jing; Wu, Di; Pan, Meng; Li, Miao; Guo, Mei; Dou, Jun

doi:10.1016/j.intimp.2017.09.019

Cited by 18 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the purpose of this study, we constructed whole-cell mixed melanoma vaccines composed of B16F10 cells, modified with H6 cDNA admixed with MSC-like cells or miPSCs in a 1:2 ratio. In contrast to CSCs (CD133 + CD44 + ) isolated from B16F10 cells [26], melanosphere-derived CSCs demonstrated the downregulation of MHC class II expression. Mixing B16H6 cells with MSCs or iPSCs resulted in enhanced priming manifested by increased infiltration of WT-Matrigel tumors by DCs with decreased infiltration by MDSCs and Tregs.…”

Section: Discussionmentioning

confidence: 75%

“…Due to the fact that CSCs express antigens differently from those expressed by more differentiated cancer cells, new immunotherapies targeting these CSCs have been intensively developed in recent years (3), and vaccination with (cancer) cells displaying stem like features has become ofinterest. Recently, Zhao et al [26] demonstrated that vaccination with CSCs (CD133 + CD44 + ) isolated from B16F10 murine melanoma cells specifically targeted B16F10-CSCs, reducing tumor growth and extending mouse survival. They also observed increased NK cell and cytotoxic splenocyte activity against B16F10 cells, as well as a reduction in NY-ESO-1 antigen expression (high in B16F10-CSCs), in melanoma tumors formed in vivo.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Novel Genetic Melanoma Vaccines Based on Induced Pluripotent Stem Cells or Melanosphere-Derived Stem-Like Cells Display High Efficacy in a murine Tumor Rejection Model

Gąbka-Buszek

Kwiatkowska-Borowczyk

Jankowski

et al. 2020

Vaccines

View full text Add to dashboard Cite

Therapeutic cancer vaccines have elicited renewed interest due to the development of immune checkpoint inhibitors. The role of these vaccines is to induce specific effector cells for killing cancer cells. Cancer stem cells (CSCs) are responsible for tumor growth and progression. Accordingly, they are targets for various cancer therapies, including immunotherapy. Here, we demonstrate the effectiveness of melanoma vaccines composed of genetically modified tumor cells admixed with melanoma stem-like cells (MSC) or induced pluripotent stem cells (iPSCs). Two vaccines were constructed. The first vaccine contained cells derived from B16F10 melanospheres (SFs) with CSC characteristics. The second vaccine contained syngeneic murine induced pluripotent stem cells (miPSCs). iPSCs or SF cells were admixed with B16F10 cells, modified with the designer cytokine Hyper-IL6(H6) (B16/H6). Control mice received B16/H6 cells, B16F10 cells or PBS. Immunization with either vaccine significantly inhibited tumor growth and increased disease-free survival (DFS) and overall survival (OS) in C57BL/6 mice. Mice treated with the SF or iPSC vaccine demonstrated increased activation of the immune response in the vaccination site and tumor microenvironment compared to those treated with B16/H6, B16F10 or PBS. Higher infiltration of dendritic cells (DCs) monocytes, and natural killer (NK) cells; lower numbers of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs); higher levels of the cytokines INFγ and IL-12 were observed with the novel vaccines than with the control treatments. In vitro restimulation of splenocytes derived from mice immunized with B16F10 cell, SF cell or miPSC lysates increased the proliferation of CD4+ T helper lymphocytes and secretion of cytokines. An increased serum titer of antibodies directed against B16F10 cells was found in mice immunized with the SF vaccine. The most effective DFS and OS extensions were reached with the miPSCs vaccine. The described results form the basis for a novel platform for the next generation of cancer vaccines composed of allogeneic cancer-specific cells modified with a molecular adjuvant gene and admixed with allogeneic miPSCs or SFs.

show abstract

Section: Discussionmentioning

confidence: 75%

Section: Discussionmentioning

confidence: 99%

Novel Genetic Melanoma Vaccines Based on Induced Pluripotent Stem Cells or Melanosphere-Derived Stem-Like Cells Display High Efficacy in a murine Tumor Rejection Model

Gąbka-Buszek

Kwiatkowska-Borowczyk

Jankowski

et al. 2020

Vaccines

View full text Add to dashboard Cite

show abstract

“…CSCs are resistant to treatment since they possess antigens different from those present in differentiated tumor cells ( Reya et al, 2001 ). Therefore, vaccination strategies relying on cells expressing stem cell antigens have gained researchers’ interest ( Dashti et al, 2016 ; Zhao et al, 2017 ). For instance, scientists have developed next-generation cancer vaccines that are more potent and targeted than conventional treatments.…”

Section: Dcs In Cancer Immunotherapymentioning

confidence: 99%

Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications

Salah

Wang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Dendritic cells (DCs) are efficient antigen-presenting cells (APCs) and potent activators of naïve T cells. Therefore, they act as a connective ring between innate and adaptive immunity. DC subsets are heterogeneous in their ontogeny and functions. They have proven to potentially take up and process tumor-associated antigens (TAAs). In this regard, researchers have developed strategies such as genetically engineered or TAA-pulsed DC vaccines; these manipulated DCs have shown significant outcomes in clinical and preclinical models. Here, we review DC classification and address how DCs are skewed into an immunosuppressive phenotype in cancer patients. Additionally, we present the advancements in DCs as a platform for cancer immunotherapy, emphasizing the technologies used for in vivo targeting of endogenous DCs, ex vivo generated vaccines from peripheral blood monocytes, and induced pluripotent stem cell-derived DCs (iPSC-DCs) to boost antitumoral immunity.

show abstract

“…CD44 has been used as a specific marker of MSCs in preclinical previous studies (95,96). It has been reported that blocking insulin-like growth factor-1 can prevent the metastatic and EMT processes of melanoma cells by downregulating the stem cell markers Sox2, OCT3/4, CD44 CD133 and deleting stem cell functional characteristics (97).…”

Section: Cd133mentioning

confidence: 99%

Effect of melanoma stem cells on melanoma metastasis (Review)

et al. 2021

Self Cite

View full text Add to dashboard Cite

Cancer stem cells (CSCs) are involved in the metastatic process, the resistance of many types of cancer to therapeutic treatments and consequently the onset of recurrences. The CSC concept therefore significantly extends our understanding of melanoma biology. More recently, melanoma stem cells (MSCs) have been described in melanoma as expressing specific biomarkers. These primitive melanoma cells are not only capable of self-renewal and differentiation plasticity, but may also confer virulence via immune evasion and multidrug resistance, and potentially, via vasculogenic mimicry and transition to migratory and metastasizing derivatives. This review will present the specific biomarkers of MSCs, including CD133, ATP binding cassette subfamily B member 5, CD271, CD20 and aldehyde dehydrogenase, which can regulate the transduction of tumor-related signals. These signal molecules can reversely act on tumor cells and regulate tumor angiogenesis, leading to the occurrence of melanoma metastasis. Targeting these specific biomarkers could inhibit the progression of melanoma and may help the development of novel therapeutic strategies for melanoma. Contents1. Introduction 2. Melanoma metastasis is modulated by molecular markers of melanoma stem cells 3. Melanoma stem cells and angiogenesis 4. Targeting molecular markers of melanoma stem cells 5. Conclusion

show abstract

Effective tumor immunity to melanoma mediated by B16F10 cancer stem cell vaccine

Cited by 18 publications

References 34 publications

Novel Genetic Melanoma Vaccines Based on Induced Pluripotent Stem Cells or Melanosphere-Derived Stem-Like Cells Display High Efficacy in a murine Tumor Rejection Model

Novel Genetic Melanoma Vaccines Based on Induced Pluripotent Stem Cells or Melanosphere-Derived Stem-Like Cells Display High Efficacy in a murine Tumor Rejection Model

Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications

Effect of melanoma stem cells on melanoma metastasis (Review)

Contact Info

Product

Resources

About